Objective: To determine the value of international prostate symptom scoring (IPSS) system in management of patients with benign prostatic hyperplasia (BPH) in Jos. Patients and Methods: This was a prospective study of 104 newly diagnosed patients with BPH from June 2006 to July 2007. Patients’ symptoms were initially evaluated by administering a pretreatment IPSS/Quality Of Life Score (QOLS). This categorized patients into mild, moderate and severe symptom groups. The mild symptom group had watchful waiting as mode of management. The moderate symptom group received doxazosin , an alpha blocker while the severe symptom group had prostatectomy. A post treatment IPSS/QOLS was administered three months after. Mean changes in IPSS/QOLS was calculated and subjected to paired student T- test for significance in changes. Spearman’s correlation coefficient was used to test significance between correlations. Results: Mean age of patients was 64.3yrs. 3 patients (2.9%), 53 patients (51.0%) and 48 patients (46.1%) fell into the minor, moderate and severe symptom categories respectively. The quality of life score correlated with IPSS. There was a mean change in symptom scores of +2.3 for the minor symptom category, -8.1 (P<0.001) for IPSS and -1.7 (P<0.001) for Quality of life score (QOLS) in the moderate symptom category, -24.6 (P<0.001) for IPSS and -4.0 (P<0.05) for QOLS in the severe symptom category. Conclusion: The study has shown that IPSS is a valuable tool in management of patients with BPH